Indaptus Therapeutics, Inc.
INDP · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | -0.30 | -0.71 | 0.84 |
| FCF Yield | -66.37% | -3.50% | -1.54% | -0.76% |
| EV / EBITDA | 0.01 | -30.67 | -51.52 | -102.78 |
| Quality | ||||
| ROIC | 271.92% | -159.92% | -101.42% | -50.55% |
| Gross Margin | 0.00% | 0.00% | 50.00% | 0.00% |
| Cash Conversion Ratio | 1.03 | 0.77 | 1.11 | 0.82 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 20.39% | -48.63% | -35.13% | -1.42% |
| Safety | ||||
| Net Debt / EBITDA | 1.17 | 0.84 | 1.37 | 2.31 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |